- Home
- RELX vs TAK Comparison
RELX vs TAK Comparison
Compare RELX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELX | TAK |
|---|---|---|
| Founded | 1903 | 1781 |
| Country | United Kingdom | Japan |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RELX | TAK |
|---|---|---|
| Price | $34.96 | $18.08 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 2.50% | ★ 2.86% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.40 | $0.04 |
| Revenue Next Year | $6.22 | $0.92 |
| P/E Ratio | ★ $20.27 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.57 | $12.99 |
| 52 Week High | $56.33 | $18.82 |
Technical Indicators
Market Signals| Indicator | RELX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 53.95 |
| Support Level | $27.57 | $14.78 |
| Resistance Level | $41.06 | $18.82 |
| Average True Range (ATR) | 0.79 | 0.23 |
| MACD | 0.92 | -0.11 |
| Stochastic Oscillator | 96.66 | 43.22 |
Price Performance
Historical ComparisonAbout RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.